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Hemorrhagic feverA new species of Ebolavirus, Bundibugyo ebolavirus, was discovered in an outbreak inwestern Uganda in Novem-
ber 2007. To study the correlation between fatal infection and immune response in Bundibugyo ebolavirus infec-
tion, viral antigen, antibodies, and 17 soluble factors important for innate immunitywere examined in 44 patient
samples. Using Luminex assays, we found that fatal infectionwas associatedwith high levels of viral antigen, low
levels of pro-inﬂammatory cytokines, such as IL-1α, IL-1β, IL-6, TNF-α, and high levels of immunosuppressor cy-
tokines like IL-10. Also, acute infected patients died in spite of generating high levels of antibodies against the
virus. Thus, our results imply that disease severity in these patients is not due to themulti-organ failure and sep-
tic shock caused by a ﬂood of inﬂammatory cytokines, as seen in infections with other Ebolavirus species.
Published by Elsevier Inc.Introduction
Ebola hemorrhagic fever (EHF) is caused by several species of
Ebolavirus. Before 2007, 2 of the 4 known Ebolavirus species were re-
sponsible for human epidemics: Zaire ebolavirus and Sudan ebolavirus.
Between 1976 and 2008, Zaire ebolavirus has caused several outbreaks
in the Democratic Republic of Congo, Republic of Congo, and Gabon,
with fatality rates as high as 90% (Sanchez et al., 2007). Sudan ebolavirus
has causedmultiple outbreaks in Sudan and the Gulu district of Uganda,
with approximately 50% case fatality. No reports of human epidemics
caused by the other 2 species, Côte d'Ivoire and Reston ebolaviruses,
have been reported. Côte d'Ivoire ebolavirus caused a single non-fatal
human infection, and Reston ebolavirus produces fatal infection in
non-human primates (Feldmann and Geisbert, 2011). In November
2007, Bundibugyo ebolavirus, a proposed new species of Ebolavirus,
was discovered in western Uganda. The outbreak began in August of
2007 and ended in December of the same year. In total, 131 cases
were identiﬁed (MacNeil et al., 2011, JID in press), with 40% case fatality
among laboratory-conﬁrmed cases (MacNeil et al., 2010). Bundibugyo
ebolavirus is most closely related to Côte d'Ivoire ebolavirus, sharing ap-
proximately 60% gene homology (Towner et al., 2008) and strong IgG
antibody cross-reactivity (Macneil et al., 2011). Interestingly, the glyco-
protein (GP) differs by 35% at the amino acid level between Bundibugyoanch, G-14, Centers for Disease
03331, USA. Fax: +1 404 639
nc.and Zaire viruses, and by 27% between Bundibugyo and Côte d'Ivoire
ebolaviruses (Towner et al., 2008).
Despite the signiﬁcant differences in genotype and mortality rates,
Zaire, Sudan, and Bundibugyo ebolaviruses induce a fairly similar clinical
manifestation in humans and display the same cell tropism in vitro
(Gupta et al., 2010;MacNeil et al., 2010). The viruses replicate primarily
inmonocytes and dendritic cells, and spread to hepatocytes, endothelial
cells, and epithelial cells to cause systemic infection (Sanchez et al.,
2007). High viremia induces secretion of pro-inﬂammatory cytokines,
such as tumor necrosis factorα (TNF-α),monocyte chemotactic protein
1 (MCP-1), macrophage inﬂammatory protein 1β (MIP-1β), and inter-
leukins (IL)-1β, 6, and 10. In the absence of substantial host immunity,
high viremia leads to septic shock seen in fatal infections, which causes
multi-organ failure and death (Feldmann and Geisbert, 2011).
During the course of the Bundibugyo EHF outbreak, preliminary
laboratory testing was performed in Uganda, and aliquots of diagnos-
tic samples were shipped to the Centers for Disease Control and Pre-
vention (CDC, Atlanta, GA, USA) for conﬁrmatory testing. We
examined circulating levels of cytokines and chemokines, viral anti-
gen Ag, IgM, and IgG levels, in anonymized diagnostic samples from
laboratory-conﬁrmed EHF cases (n=44). Of the 44 samples, 11 were
collected during the acute stage of the disease from individuals who
died of EHF, 12 were paired samples collected from EHF survivors dur-
ing the acute and convalescent stages, and 9 were collected from EHF
survivors during the convalescent stage. Additionally, as a control, we
examined the same serological parameters in samples collected from
10 healthy African health careworkers employed at the hospital and in-
volved in outbreak response activities but showed no evidence of the
disease. We found that the serum circulating cytokine proﬁles of
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Fig. 1. Antigen (Ag), IgM, and IgG levels in patients infected with Bundibugyo ebolavirus.
Antigen (A), anti-Ebolavirus IgM (B), and anti-Ebolavirus IgG (C) levels were determined
by immunocapture or direct enzyme-linked immunosorbent assay (ELISA) in samples col-
lected from non-surviving (diamonds; n=11) and surviving patients (triangles; n=12)
during the acute stage of Bundibugyo ebolavirus infection, and in samples from convales-
cent patients (circles; n=21). Each point represents 1 sample. Median values are
shown as dashed lines. Viral antigen levels were signiﬁcantly higher in acute samples
from non-survivors than survivors (**pb0.005). We saw no differences in anti-Ebolavirus
IgM and IgG levels between non-surviving and surviving patients.
120 M. Gupta et al. / Virology 423 (2012) 119–124patients infected with Bundibugyo ebolavirus differed signiﬁcantly from
those produced by Zaire and Sudan ebolaviruses.
Results
Ag, IgM, and IgG levels in acute and convalescent patients infected with
Bundibugyo ebolavirus
A total of 44 samples of blood plasma or sera were tested for
Bundibugyo ebolavirus-speciﬁc Ag and antibodies. Samples were di-
vided into acute and convalescent groups. The acute samples were
collected 0–11 days after onset of illness from 11 patients who did
not survive the infection (acute non-survivors), and 12 surviving pa-
tients (acute survivors). No differences were noted in the time be-
tween illness onset and sample collection between acute survivors
and acute non-survivors (median=7.5 days among survivors,
7.0 days among non-survivors; p=0.6639). The convalescent group
included 21 samples collected during the convalescent stage of the
disease, 35–64 days after illness onset; 12 of these samples were col-
lected from the same patients used for the acute survivors group,
while the remaining 9 did not have a paired acute sample. Ag titers
ranged from150 to 12,150 amongacute non-survivors (median=4050;
Fig. 1a; Antigen titers are dilutions corrected at OD410>0.1); 6 of the 11
acute non-survivors had titers of 4050. Ag titerswere signiﬁcantly lower
(50–4050; median=150) in the acute survivors group, and 3 of the
samples did not contain detectable Ag. As expected, no Ag was detected
in convalescent patients (Fig. 1a).
We determined the levels of anti-Bundibugyo ebolavirus IgM and
IgG antibodies using capture ELISA. Four of the 11 non-survivors
had IgM titers of 1:2560, 4 had no detectable antibodies, and 3 had ti-
ters ranging from 1:40 to 160. IgG levels in these patients ranged from
1:40 to 2560; 3 of the 11 samples had IgG titers of 1:2560, and 4 had
titers of 1:640. Two samples did not have any detectable anti-Ebola
IgG (Fig. 1b).
Anti-Ebolavirus IgM levels were similar in acute survivors, ranging
from 1:160 to 2560. Five of the 12 patients had titers of 1:640 and 3
had titers of 1:2560; no IgM was detected in 3 samples. Anti-Ebola
IgG levels in these patients were also similar to those of acute non-
survivors (1:160–2560). Three of the 12 patients had titers of
1:2560, 4 had titers of 1:640, and 4 had titers of 1:160. Patients
with high levels of IgM also had corresponding levels of IgG; for ex-
ample, 3 patients had titers of 1:640–2560 of both IgM and IgG
(Figs. 1b, c).
Convalescent patients expressed anti-Ebolavirus IgM levels
35–64 days post-infection. Twelve of the 21 patients had IgM levels
ranging 1:40–640, and 1 sample reached 1:2560. All convalescent pa-
tients also expressed anti-Ebolavirus IgG. Seven patients had titers of
1:2560, and 8 had titers of 1:10,240 (Figs. 1b, c). Samples from the
10 individuals with no disease were serologically negative for both
anti-Bundibugyo Ebolavirus IgM and IgG and negative for Ebolavirus an-
tigen (anti-Bundibugyo ebolavirus IgM and IgG titer b40 and Ebolavirus
antigen titer b50). A table of contents summarizes laboratory results
of viral antigen, anti-Bundibugyo ebolavirus IgM and IgG antibodies,
time of sample collection from the onset of illness and outcome of the
disease on all 44 samples collected is shown (Table 1).
Reduced IL-1α, IL-1β, IL-6, and TNF-α levels, and increased IL-10 levels in
acute samples
In order to identify the cytokines affected by Bundibugyo ebola-
virus infection, we compared cytokine levels in acute-stage and
convalescent-stage samples. We found that several pro-
inﬂammatory cytokines were not induced during acute disease. IL-
1α and IL-1βwere signiﬁcantly lower in acute patients than in conva-
lescent patients (pb0.005). Indeed, IL-1α was undetectable in 23 of
the 24 acute patients, and IL1β was undetectable in 20 of the 24patients (Fig. 2A). Similarly, inﬂammatory cytokine levels were also
signiﬁcantly lower in acute than in convalescent patients (pb0.005).
Median TNF-α levels were 4-fold lower in acute than convalescent
patients (10 pg/mL vs 42.7 pg/mL, respectively; Fig. 2B), while median
IL-6 levels were 2 logs lower in acute patients than in convalescent pa-
tients (15 pg/mL vs 299 pg/mL, respectively; Fig. 2A). Interestingly, we
found that the levels of the anti-inﬂammatory immunosuppressor IL-10
were approximately 20-fold higher in the acute group than in the con-
valescent group (144 pg/mL vs 6 pg/mL, respectively; Fig. 2B). Together,
these data suggest that patients generally express low levels of inﬂam-
matory cytokines during the acute stage of Bundibugyo EHF.
We found no signiﬁcant differences in IFN-γ levels between sam-
ples from controls and acute patients or between acute and convales-
cent patients. We found that IFN-α2 levels were signiﬁcantly higher
in acute patients than in convalescent patients (p=0.02), but not
Table 1
Summary of laboratory results of viral antigen, anti-Bundibugyo Ebolavirus IgM and IgG antibodies, diagnostic PCR results (done in the ﬁeld), sample collection time from the onset
of illness and outcome of disease on all 44 samples collected during outbreak. ND means not determined.
Sample type Case ID Diagnostic PCR Collection time Ag IgM IgG Outcome
Unpaired, acute 603 Positive 11 4050 40 b40 Dead
Unpaired, acute 609 Positive 6 4050 2560 2560 Dead
Unpaired, acute 610 Positive 8 12,150 2560 2560 Dead
Unpaired, acute 614 Positive 9 4050 b40 2560 Dead
Unpaired, acute 627 Positive 4 450 b40 640 Dead
Unpaired, acute 630 Positive 0 150 b40 640 Dead
Unpaired, acute 631 Positive 5 4050 160 160 Dead
Unpaired, acute 633 Positive 9 12,150 2560 640 Dead
Unpaired, acute 634 Positive Unknown 4050 b40 640 Dead
Unpaired, acute 636 Positive 7 4050 2560 b40 Dead
Unpaired, acute 638 Positive 7 150 40 40 Dead
Paired 605 ND 2 b50 b40 160 Alive
605 42 b50 b40 160 Alive
Paired 611 Positive 9 450 2560 160 Alive
611 47 b50 160 2560 Alive
Paired 612 Positive 9 450 2560 640 Alive
612 53 b50 640 2560 Alive
Paired 613 Positive 7 1350 640 160 Alive
613 48 b50 640 10,240 Alive
Paired 616 Positive 10 150 640 640 Alive
616 55 b50 b40 10,240 Alive
Paired 617 Positive 9 50 640 640 Alive
617 46 b50 640 10,240 Alive
Paired 619 Positive 5 b50 b40 640 Alive
619 44 b50 b40 160 Alive
Paired 621 Positive 8 4050 160 2560 Alive
621 47 b50 40 2560 Alive
Paired 623 Positive 5 50 b40 160 Alive
623 44 b50 b40 10,240 Alive
Paired 626 Positive 7 150 640 ND Alive
626 36 b50 40 10,240 Alive
Paired 628 Positive 7 b50 640 2560 Alive
628 47 b50 40 2560 Alive
Paired 635 Positive 8 1350 2560 2560 Alive
635 35 b50 640 2560 Alive
Unpaired, convalescent 602 ND 62 b50 b40 10,240 Alive
Unpaired, convalescent 604 ND 45 b50 b40 160 Alive
Unpaired, convalescent 607 ND 45 b50 160 ND Alive
Unpaired, convalescent 608 ND 46 b50 640 2560 Alive
Unpaired, convalescent 622 ND 40 b50 40 10,240 Alive
Unpaired, convalescent 624 ND 47 b50 2560 2560 Alive
Unpaired, convalescent 629 ND 62 b50 b40 40,960 Alive
Unpaired, convalescent 632 ND 64 b50 b40 640 Alive
Unpaired, convalescent 637 ND 46 b50 160 10,240 Alive
121M. Gupta et al. / Virology 423 (2012) 119–124higher than in controls. MCP-1 levels were signiﬁcantly higher in
acute patients and convalescent patients than in controls (Fig. 2C). In-
terestingly, in convalescent patients, MCP-1 levels were even signiﬁ-
cantly higher than in acute patients (median=4637 pg/mL vs
2387 pg/mL; pb0.05; Fig. 2C).
To further examine these trends, we compared cytokine levels in
acute or convalescents sampleswith the samples from the 10 individuals
with no evidence of disease. As we previously observed, IL-1α, IL-1β,
TNF-α, and IL-6 were lower, and IL-10 higher, in acute samples com-
pared to samples from control individuals. Furthermore, the levels of
these cytokines did not differ between the control samples and conva-
lescent samples.IFN-α2, IFN-γ, and IL-10 levels are higher in acute non-survivors than in
acute survivors
In order to identify cytokines associated with disease severity, we
speciﬁcally examined cytokine levels in samples collected during the
acute stage of the disease, and stratiﬁed these values according to pa-
tient survival. IFN-α2 levels were signiﬁcantly higher in non-survivors
than in survivors (median=45 pg/mL vs 1 pg/mL, respectively;
pb0.05). Ten of the 12 survivors had no detectable IFN-α2 levels. Sim-
ilarly, IFN-γ levels were signiﬁcantly higher in non-survivors than insurvivors (median=30 pg/mL vs 9 pg/mL, respectively). Interestingly,
our results show that IL-10 levels were 3-fold higher in non-survivors
than in survivors (median=597 pg/mL vs 169 pg/mL, respectively;
pb0.005; Fig. 3). We did not observe signiﬁcant differences in IL-6,
MCP-1, TNF-α, IL-1α, or IL-1β levels between these 2 groups.Discussion
The Bundibugyo ebolavirus outbreak produced 131 reported cases
with an approximate mortality rate of 40%. We examined 11 samples
collected during the acute stage of the disease from non-survivors,
and 12 collected from survivors, as well as 21 samples collected
from convalescent patients. Our data show that median Ag titers
were about 25-fold higher in acute non-survivors than in acute survi-
vors (150 vs 4050). Interestingly, individuals who had high viral Ag
titers had correspondingly high IgG titers (data not shown). Elevated
IgG levels in non-survivors were rarely observed in previous out-
breaks (Baize et al., 1999, 2002; Ksiazek et al., 1999), and suggest
that patients infected with Bundibugyo ebolavirusmay develop higher
cellular and humoral immunity than do patients infected with other
Ebolavirus species. We have previously shown that monocyte cell
death is delayed in Bundibugyo ebolavirus infection compared to
Zaire ebolavirus infection in vitro (Gupta et al., 2010). It is possible
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Fig. 2. Cytokine and chemokine proﬁles in samples from control, acute-stage, and convalescent patients. A. IL-1α, IL-1β, TNF-α, and IL-6 levels. B. IL-10 levels. C. IFN-γ, IFN-α2, and
MCP-1 levels. Each dot represents 1 sample, and dashes (−) represent median values. *Indicates pb0.05, **indicates pb0.005, ***indicates pb0.0005.
122 M. Gupta et al. / Virology 423 (2012) 119–124that this delay in monocyte and/or lymphocyte death in Bundibugyo
ebolavirus-infected patients activates humoral immunity. In spite of
the anti-viral IgM and IgG response in non-survivors, these patients
were unable to control infection and succumbed to it. However it is
possible that antibodies generated during infection in non-survivors
are simply a reﬂection of viral load and are not necessarily controlling
viral infection.
We observed signiﬁcantly lower IL-1α, IL-1β, IL-6, and TNF-α
levels in acute samples than in convalescent or control samples, suggest-
ing that these cytokines are downregulated by Bundibugyo ebolavirus. IL-
1α possesses hemopoietic activity (Arend, 2002) and induces CD4 T-cell
and B-cell proliferation, as well as TNF-α release by endothelial cells
(Smirnova et al., 2002). IL-1α synthesis is inhibited by IL-10Non-
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In addition to previous studies, which report elevated IL-6 and TNF-α
levels in samples from non-surviving patients, we found no differences
in the levels of these cytokines between the acute survivor and non-
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This suggests that, unlike other Ebolavirus species, Bundibugyo ebolavirus
does not induce a strong inﬂammatory response.*
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patients had signiﬁcantly higher levels of IL-10 than did survivors
(Baize et al., 2002; Hutchinson and Rollin, 2007; Villinger et al.,
1999). IL-10 is an anti-inﬂammatory immunosuppressor cytokine pri-
marily produced by the monocytes. It downregulates Th1 response
and inhibits CD8 T-cell response (O'Garra et al., 2008), and suppresses
IFN-γ, IL-2, and TNF-α, thus inhibiting the inﬂammatory response
(Brockman et al., 2009). Recently, IL-10 has been found to block nitric
oxide synthesis in monocytes, affecting the anti-viral function of
these cells (Burgner et al., 1999; Moreira et al., 2010). High levels of
IL-10 have been observed in acute-stage patients infected with
other Ebolavirus species, suggesting that the Ebolavirus motif that in-
duces IL-10 secretion has been evolutionarily conserved, and has con-
tinued to suppress host immunity. Therefore, we think that high IL-10
levels detected a few days after illness onset may be potential marker
of fatal outcome. Possibly Ebolavirus infected monocytes and dendritic
cells are the main source of IL-10 induction. Studies are underway to
conﬁrm this hypothesis.
The release of pro-inﬂammatory cytokines and chemokines has
been proposed to cause fatality in Ebolavirus infection (Feldmann
and Geisbert, 2011), and previous studies report high levels of IFN-
γ, IFN-α, and TNF-α in cases of fatal Ebolavirus infection (Baize et
al., 1999; Villinger et al., 1999). Interestingly, although we also
found higher levels of IFN-γ and IFN-α in non-survivors than in sur-
vivors, but did not see signiﬁcant differences in TNF-α levels between
the 2 groups. A prominent feature of Bundibugyo ebolavirus, therefore,
is downregulation of inﬂammatory cytokines and upregulation of
immunosuppressor cytokines. Our study suggests that high levels of
inﬂammatory cytokines, which can lead to septic shock, do not
seem to cause death in Bundibugyo ebolavirus infection.
A previous study performed in asymptomatic patients reported
that individuals seropositive for Ebolavirus express high levels of in-
ﬂammatory cytokines (Leroy et al., 2000). Our results show a similar
trend.
In conclusion, we have shown that pro-inﬂammatory cytokines,
such as TNF-α, IL-1β, IL-1α, and IL-6 are not induced in non-
surviving patients, suggesting that death in these patients is not
caused by septic shock from a cytokine ﬂood, as previously suggested
for other species of Ebolavirus. However, IL-10 was higher in non-
survivors than in survivors, as observed previously in outbreaks of
both Zaire and Sudan ebolavirus species (Hutchinson and Rollin,
2007; Villinger et al., 1999). Studies to investigate the role of IL-10
in host immunity against different species of Ebolavirus are currently
underway.
Materials and methods
Samples
During outbreak response, aliquots of diagnostic samples were
shipped to the CDC for conﬁrmatory testing. All samples were collected
as part of outbreak activities, anonymized, and identiﬁed only as fatal
and nonfatal cases. Human subject review of this protocol was per-
formed and approved by the CDC Institutional Review Board. Upon col-
lection, samples were taken to Biosafety level-4 (BSL-4) and stored
at −80 °C until further processing. Plasma and serum were separated
by centrifugation and stored in liquid nitrogen. All samples were inacti-
vated by gamma-irradiation (5×106 rads) before determining Ag, anti-
body, cytokine, and chemokine levels in a BSL-2 laboratory.
Viral Ag assay
Levels of circulating Ebolavirus Ag in plasma and sera were esti-
mated using a capture enzyme-linked immunosorbent assay (ELISA)
as previously described (Ksiazek et al., 1999). Brieﬂy, Flexiplates
(Becton, Dickinson and Co., Franklin Lakes, NJ, USA) were coatedovernight at 4 °C with mouse ascitic ﬂuid containing a mixture of 7
mouse monoclonal antibodies raised against viral protein VP40, GP,
and nucleoprotein (NP) derived from Zaire 1976 and Sudan 1976
samples of Ebolavirus. Plasma and serum samples were serially dilut-
ed in 5% skim milk in phosphate-buffered saline (PBS; pH 7.2) with
0.1% Tween-20 (hereafter referred to as blocking buffer), and incu-
bated at 37 °C for 1 h. Captured Ag was detected using polyclonal
anti-Zaire ebolavirus serum produced in rabbits, and visualized with
a goat anti-rabbit horseradish peroxidase (HRP) conjugate and 2,2′-
azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) diammonium (ABTS)
substrate (all from Kirkegaard and Perry Laboratories, Gaithersburg,
MD, USA). Optical density at 410 nm (OD410) of each sample placed
into control wells coated with normal mouse ascitic ﬂuid was sub-
tracted from the OD of the same sample placed into the corresponding
well coated with anti-Ebolavirusmonoclonal antibodies to derive a cor-
rected OD. The highest sample dilution that resulted in a corrected OD
≥0.1 was designated as the viral Ag titer of the sample.
Anti-Ebolavirus IgG detection assay
Levels of circulating anti-Bundibugyo ebolavirus-speciﬁc anti-
bodies were detected using capture ELISA as previously described
(Ksiazek et al., 1999). Flexiplates were coated overnight at 4 °C with
lysates of Vero E6 infected with Bundibugyo ebolavirus or with unin-
fected Vero E6 cell lysate. Plasma and serum samples were serially di-
luted in skim milk as described above. Capture antibodies were
detected using mouse anti-human IgG-HRP conjugate and visualized
with ABTS substrate as above. The highest sample dilution that
resulted in a corrected OD≥0.2 was designated as the antiviral IgG
titer of the sample.
Anti-Ebolavirus IgM assay
Anti-Ebolavirus IgM antibodies were detected by sandwich ELISA
as previously described (Ksiazek et al., 1999). Flexiplates were coated
with anti-mouse antibodies (Biosource International, Camarillo, CA,
USA) overnight at 4 °C. Serially diluted samples were prepared in
skim milk as described above and incubated for 1 h at 37 °C. To esti-
mate the amount of anti-Ebolavirus-speciﬁc antibodies, samples
were incubated with Bundibugyo ebolavirus-speciﬁc cell slurry or
with normal cell slurry for 1 h at 37 °C. Ebolavirus-speciﬁc antibodies
were detected using polyclonal anti-Ebolavirus antibodies and goat
anti-mouse-HRP conjugate. Color was developed with ABTS substrate
as described above. The highest dilution of sample that resulted in a
corrected OD ≥0.1 was designated as the anti-viral IgM titer of the
sample.
Cytokine detection using Luminex beads
Levels of 17 cytokines and chemokines were detected using Lumi-
nex technology (Bio-Rad Laboratories, Hercules, CA, USA). One cus-
tomized cytokine kit was used according to manufacturer's
instructions. The target cytokines were IL-1α, IL-1β, IL-10, IL-6, IL-
12p40, IL-12p70, MCP-1, MIP-1α, MIP-1β, TNF-α, TNF-β, interferon
α2 (IFN-α2), IFN-γ, IFN-inducible protein (IP-10), T-cell growth fac-
tor α (TGF-α), regulated-on-activation, normal T-cell expressed,
and secreted (RANTES), and vascular cell adhesion molecule-1
(VCAM-1).
After inactivation by irradiation, the samples were processed
under BSL-2 conditions; previous studies show that the irradiation
process does not affect the cytokine assay (Mahanty et al., 1999).
Brieﬂy, 25 μL of plasma or serum were diluted 1:4 and incubated
with antibody-coupled beads for 1 h at room temperature. The
beads were then incubated at room temperature with detector anti-
body for 1 h, and with streptavidin-phycoerythrin for 30 min. Finally,
the complexes were washed and resuspended in running buffer. The
124 M. Gupta et al. / Virology 423 (2012) 119–124beads were washed 3 times between each step according to manufac-
turer's instructions. 100 beads per cytokine were acquired using
Luminex 400 (Luminex Corp., Austin, TX, USA). Mean ﬂuorescent in-
tensity was measured to calculate ﬁnal cytokine concentration in
pg/mL.
Statistical analysis
Statistical analyses were performed using standardized software
(SAS v9.2). Based on a reliable detection limit of 1 pg/mL, individually
measured cytokine values below this value were designated as 1 pg/
mL for analytic purposes. Differences in cytokine values between
study groups were assessed byWilcoxon rank sum test; p-values rep-
resent 2-sided p-values, and p valuesb0.05 were considered statisti-
cally signiﬁcant.
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